PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia

Core Insights - ResMed presented 13 new clinical studies at SLEEP 2024, highlighting the effectiveness of positive airway pressure (PAP) therapy for obstructive sleep apnea (OSA) [1][6] Group 1: Prevalence of Insomnia - A study indicated that approximately 17% of adults in Northern America, Latin America, and the Caribbean suffer from insomnia, emphasizing the need for prioritizing sleep health in public health initiatives [2] Group 2: OSA and Depression - Research found that among OSA patients, nearly 17% had depression, with 25.5% of those being women. Patients with depression exhibited a higher burden of comorbidities and lower adherence to PAP therapy, particularly among women [4] Group 3: Impact of PAP Therapy - A study on patients with OSA and comorbid insomnia (COMISA) revealed that those who adhered to PAP therapy had significantly lower all-cause hospitalizations (0.09 vs 0.13) and emergency room visits (0.46 vs 0.60) compared to those with lower adherence, indicating improved health outcomes [7]